Anduze-Faris BM et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 14: 517-524, 2000.

Baldanti F et al. Reappearance of human cytomegalovirus DNA in blood of HIV-positive patients after 2.5 years of HAART. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 271, 2000.

Baril L et al. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS 14: 2593-2596, 2000b.

Bell WR et al. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in cytomegalovirus prophylaxis trial (ACTG 204). Medicine 76: 369-380, 1997.

Blanshard C et al. A randomized controlled study of foscarnet vs ganciclovir in induction therapy of cytomegalovirus gastrointestinal infections in AIDS. Ninth International Conference on AIDS, Berlin, abstract B11-4, 1993.

Borucki MJ et al. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res 64: 103-111, 2004.

Bowen EF et al. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10: 1515-1520, 1996.

Bowen EF et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 11(7): 889-893, 1997.

Bowen EF et al. Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. AIDS 12(6): 605-611, 1998.

Brosgart CL et al. A randomized placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. AIDS 12(3): 269-277, 1998.

Brown F et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clinical Pharmacokinetics 37(2): 167-176, 1999.

Bush CE et al. Multicenter evaluation of CMV reactivation in HIV-infected women at potential risk for CMV disease. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 273, 2000.

Casado JL et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. AIDS 13(12): 1497-1502, 1999.

Chevret S et al. Usefulness of the cytomegalovirus (CMV) antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS. Clinical Infectious Diseases 28(4): 758-763, 1999.

Cochereau-Massin I et al. Intravitreal ganciclovir: a 3-year experience. Third European Conference on Clinical Aspects and Treatment of HIV Infection, Paris, abstract 023, 1992.

Couderc L-J et al. Combination ganciclovir and foscarnet in cytomegalovirus (CMV)-related neurological diseases in AIDS patients. Third Conference on Retroviruses and Opportunistic Infections, Washington, abstract 173, 1996.

Crumpacker C et al. Oral vs intravenous ganciclovir as maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS. First National Conference on Human Retroviruses and Related Infections, Washington, abstract 538, 1993.

Danner S et al. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 9: 471-477, 1995.

Deayton J. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific antiCMV therapy. AIDS13(10): 1203-1206, 1999.

Deayton JR et al. Efficacy of the regenerating immune system in the inhibition of CMV replication after highly active antiretroviral therapy (HAART). Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract PL5.4.1. AIDS 14(suppl 4):S5, 2000a.

Deayton JR et al. Recurrence of CMV viraemia and development of anti-CMV drug resistance in patients receiving highly active antiretroviral therapy after CMV retinitis. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract PL5.4.2, 2000. AIDS 14(suppl 4):S5-S6, 2000b.

Deayton JR et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 14(9): 1163-1170, 2000c.

Deayton JR et al. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients taking highly active antiretroviral therapy. Lancet 363: 2116-2121, 2004.

Dieterich D et al. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomised, double-blind placebo-controlled multicenter study. Journal of Infectious Diseases 167: 278-282, 1993a.

Dieterich D et al. Treatment of gastrointestinal cytomegalovirus infection using twice daily administration of foscarnet in AIDS patients. First National Conference on Human Retroviruses and Related Infections, Washington, abstract 513, 1993b.

Dodt KK et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigeniemia test. AIDS 11: 21-28, 1997.

Drew WL et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. New England Journal of Medicine 333: 615-620, 1995.

Drew WL et al. Prevalence of ganciclovir-resistant cytomegalovirus during oral ganciclovir prophylaxis. Third Conference on Retroviruses and Opportunistic Infections, Washington, late-breaking abstract, 1996.

Drew WL et al. In vivo anti-CMV activity and safety of oral 1263W94 in HIV-infected subjects with asympotomatic CMV shedding. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-25, 1998.

Feinberg J et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. Journal of Infectious Diseases 177: 48-56, 1998.

Finkelstein et al. CMV shedding and the risk of end-organ disease. 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, abstract 505, 1997.

French MA et al. Restoration of CD4+ T-cell Responses to Cytomegalovirus is Short-lived in Severely Immunodeficient HIV Patients Responding to Highly Active Antiretroviral Therapy. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 239, 2004.

Gallant JE et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. Journal of Infectious Diseases 166: 1223-1227, 1992.

Ganciclovir Implant Study Group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. New England Journal of Medicine 337(2): 83-90, 1997.

Gilquin J et al. Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors. AIDS. 11(13):1659-1660, 1997.

Griffiths PD et al. Detection of cytomegalovirus in samples from patients enrolled in ACTG 204/Glaxo Wellcome 123-014. Third Conference on Retroviruses and Opportunistic Infections, Washington, abstract 10, 1996.

Grzywacz M et al. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients. Journal of Medical Virology 59(3):323-328, 1999.

Hardy D et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. European Journal of Clinical Microbiology and Infectious Diseases 13 Suppl 2:S34-40, 1994.

Hardy WD et al. Loss of hearing as a sign of relapse in CMV polyradiculopathy. Second National Conference on Human Retroviruses and Related Infections, Washington, abstract 287, 1995.

Hirsch M. The treatment of cytomegalovirus in AIDS - more than meets the eye. Editorial, New England Journal of Medicine 326(4):264-266, 1992.

Huang E-S et al. Irreversible inhibition of human cytomegalovirus replication by topoisomerase II inhibitor, etoposide: a new strategy for the treatment of human CMV infection. Antiviral Research 17:17-32, 1992.

Jabs D. Treatment of CMV retinitis - 1992 (editorial). Archives of Ophthalmology 110:185-6, 1992.

Jabs DA et al. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS; the Cytomegalovirus Retreatment Trial. Archives of Ophthalmology 114:23-33, 1996.

Jabs DA et al. Incidence of resistant cytomegalovirus (CMV) in patients being treated for CMV retinitis. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 262, 1998.

Jabs DA et al. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS 16(6):877-887, 2002.

Jacobson M et al. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrobial Agents and Chemotherapy 33(5):336-741, 1989.

Jacobson MA et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349(9063):1443-1445, 1997.

Jacobson MA et al. Natural history and outcome of new AIDS-related CMV retinitis cases diagnosed in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 30(1):232-233, 2000.

Jalali S et al. Effect of highly active antiretroviral therapy on the incidence of HIV-related cytomegalovirus retinitis and retinal detachment. AIDS Patient Care 14(7):343-346, 2000.

Johnson S et al. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clinical Infectious Diseases 32(5):815-819, 2001.

Jouan M et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 15(1):23-31, 2001.

Karavellas MP et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. Journal of Infectious Diseases 179(3):697-700, 1999.

Kim YS et al. Polyradiculopathy due to cytomegalovirus: Report of two cases in which improvement occurred after prolonged therapy and review of the literature. Clinical Infectious Diseases 17:32-37, 1993.

Kirsch LS et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. J Ophthalmology 119:466-476, 1995a.

Kirsch LS et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Ophthalmology 102(4):533-543, 1995b.

Kupperman BD et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. American Journal of Ophthalmology 115:575-582, 1993.

Kupperman BD et al. Efficacy of the ganciclovir implant for the treatment of relapsing CMV retinitis. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, abstract 303, 1997.

Lalezari JP et al. A comparison of the safety and efficacy of 3g, 4.5g and 6g doses or oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis. Eleventh International Conference on AIDS, Vancouver, abstract Th.B.305, 1996.

Lalezari JP et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Annals of Internal Medicine 126(4):257-63, 1997.

Lalezari JP et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17(4):339-344, 1998.

Lalezari JP et al. High dose oral ganciclovir treatment for cytomegalovirus retinitis. Journal of Clinical Virology 24(1-2):67-77, 2002.

Lee CA et al. Progression of HIV disease in a hæ­¯philiac cohort followed for 11 years and the effect of treatment. British Medical Journal 303:1093-1096, 1991.

Lieberman RM et al. Antisense oligonucleotide (fomivirsen sodium) treatment of CMV retinitis unresponsive to other antiviral therapies. Association for Vision Research and Ophthalmology, Fort Lauderdale, abstract, 1997.

Lowance D et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New England Journal of Medicine 340(19):1462, 1999.

MacDonald JC et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. Journal Infectious Diseases 177:1182-1187, 1998.

Macdonald JC et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus. Ophthalmology 107(5):877-881, 2000.

Martin DF et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Archives of Ophthalmology 112:1531-1539, 1994.

Martin DF et al. Ganciclovir implant exchange. Timing, surgical procedure, and complications. Archives of Ophthalmology 115:1389-1394, 1997.

Martin DF et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. New England Journal of Medicine 340:14: 1063-1070, 1999.

Martin D et al. A controlled trial of valganciclovir as induction therapy for Cytomegalovirus retinitis. New England Journal of Medicine 346(15):1119-1126, 2002.

Mathieson S et al. 6g vs 3g doses of oral ganciclovir in maintenance treatment of CMV retinitis. Eleventh International Conference on AIDS, Vancouver, abstract Tu.B.2184, 1996.

Meinert CL et al. Mortality in patients with the acquired immune deficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. New England Journal of Medicine 326(4):213-220, 1992.

Michaels S et al. Incidence and spectrum of AIDS-defining illnesses among persons treated with antiretroviral drugs. Clinical Infectious Diseases 29(2):468-469, 1999.

Muccioli C et al Fomivirsen safety and efficacy in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract LB6, 1998.

Nelson M et al. Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with AIDS. American Journal of Gastroenterology 86(7):876-891, 1991.

Nguyen QD et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. American Journal of Ophthalmology 129(5):634-639, 2000.

Nieto FJ et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 94:922-927, 1996.

Okubo S et al. Significance of coinfections by HIV, HTLV, Epstein Barr virus, and cytomegalovirus for immunological conditions in Japanese hæ­¯philiacs. AIDS 88(2):318-319, 1988.

O'Moore EJ et al. Ocular manifestations of CMV infection in AIDS patients in the era of HAART. Fourth Annual Meeting of the British HIV Association, Oxford, abstract 6, 1998.

Orellana J et al. Intravitreal foscarnet therapy for patients with recurrent progressive cytomegalovirus (CMV) retinitis. Eleventh International Conference on AIDS, Vancouver, abstract We.B.3216, 1996.

Palella FJ et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860, 1998.

Palestine AG et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Annals of Internal Medicine 115(9):665-673, 1991.

Palestine AG et al. Treatment of cytomegalovirus (CMV) retinitis with ISIS 2922. Investigative Ophthalmology and Visual Science 36(suppl):S181, 1995.

Pan S-C et al. The correlation between the development of cytomegalovirus retinitis and the cytomegalovirus-specific immunologic reactivity of T-cells. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract PL5.5, 2000. AIDS 2000;14(suppl 4):S6.

Perez H et al. Absence of reactivation of cytomegalovirus (CMV) retinitis after discontinuation of CMV maintenance therapy in patients on HAART. Thirteenth International AIDS Conference, Durban, abstract 359, 2000.

Pescovitz MD et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrobial Agents and Chemotherapy 44(10):2811-2815, 2000.

Petersen E et al. Therapy with human monoclonal antibody (Mab) to cytomegalovirus (TI-23). Seventh International Conference on AIDS, Florence, abstract WB 2291, 1991.

Rabkin CS et al. Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus-infected hemophilia patients. Journal of Infectious Diseases 168:1260-1263, 1993.

Rahhal FM et al. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Annals of Internal Medicine 125(2):98-103, 1996.

Sabin CA et al. The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of hæ­¯philic men followed for up to 13 years from seroconversion. Epidemiology and Infection 114(2):361-372, 1995.

Sabin C et al. Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. Journal of Infectious Diseases 181(5):1800-3, 2000.

Salmon-Ceron D et al. Is HIV disease progression influenced by CMV co-infection? Tenth Internationally Conference on AIDS, Yokohama, abstract PB0018, 1994.

Shinkai M et al. Utility of urine and leucocyte cultures and plasma DNA PCR for identification of AIDS patients at risk for developing human cytomegalovirus disease. Journal of Infectious Diseases 175: 302-308, 1997.

Schrier RD et al. Pathogenesis of CMV Immune Recovery Uveitis. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 31, 2001.

SOCA Research Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Annals of Internal Medicine 126:264-274, 1997a.

SOCA Research Group. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the monoclonal antibody cytomegalovirus retinitis trial. Archives of Ophthalmology 115(12):1528-1536, 1997b.

Song MK et al. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina 20(2):151-155, 2000.

Spector SA et al. A randomized, controlled trial of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. Journal of Infectious Diseases 168:557-563, 1993.

Spector SA et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. New England Journal of Medicine 334(23):1491-1497, 1996a.

Spector SA et al. Plasma cytomegalovirus DNA load predicts CMV disease and survival in AIDS patients. J Clinical Investigation 101:2, 407-502, 1998.

Stoehr A et al. Controlled randomized trial of ganciclovir (GCV) in comparison to half dose combination therapy with GCV and foscarnet (PFA) in CMV retinitis. Third International Congress on Drug Therapy in HIV Infection, Birmingham, abstract OP3.4, 1996.

Squires KE et al. Oral ganciclovir versus intravenous ganciclovir maintenance therapy for cytomegalovirus retinitis in patients with AIDS: preliminary results of a phase III study. First National Conference on Human Retroviruses and Related Infections, Washington, abstract 540, 1993.

Taskintuna I et al. Adverse events and autopsy findings after intravenous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 104(11):1827-1836, 1997.

Thiebaut R et al. Is CMV a cardiovascular risk factor in HIV-1 infected patients? Supra study, Bordeaux, France 1999. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 296, 2001.

Torriani FJ et al. Lymphoproliferative responses to CMV predict CMV retinitis reactivation in patients who discontinued CMV therapy. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 250, 1999.

Torriani FJ et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 14(2):173-180, 2000.

Touloumi G et al. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19(1):89-97, 1998.

Tural C et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 177:1080-1083, 1998.

Van den Horn GJ et al. Effects of protease inhibitors on the course of CMV retinitis in relation to CD4 lymphocyte responses in HIV positive patients. British Journal of Ophthalmology 82(9):988-990, 1998.

Vrabec TR et al. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 105:1259-64, 1998.

Walsh J et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 12(6):613-618, 1998.

Webster A et al. CMV infection and progression towards AIDS in hæ­¯philiacs with HIV infection. Lancet 2(8654):63-66, 1989.

Weinberg A et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immune deficiency syndrome and cytomegalovirus retinitis. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 790, 2003.

Whitcup SM et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. Journal of the American Medical Association 282: 17, 1633-1637, 1999.

Whitley RJ et al. Cytomegalovirus retinitis--evolving therapies in a new era. N Engl J Med 340: 1109-1110, 1999.

Wohl D et al. CMV viremia and the risk of CMV end-organ disease or death in patients with AIDS. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 274, 2000.

Wohl DA et al. CMV viremia is predictive of death among persons with AIDS independent of plasma HIV RNA level and CD4+ cell count. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 789, 2003.

Youle MS et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 8(5):641-649, 1994

Yust I et al. The effect of HAART on retinal and extraocular cytomegalovirus infection in patients with AIDS in Europe. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract PL 5.4.1, 2000. AIDS 14(suppl 4):S126, abstract P375, 2000.

Zurlo J et al. Relationship between CMV culture positivity and circulating CD4 count in patients with HIV infection. Sixth International Conference on AIDS, San Francisco, abstract ThB 431, 1990.